Tamar Jaghasbanian  
Regulatory Affairs Manager  
Medtronic MiniMed, Inc.  
18000 Devonshire St.  
Northridge, CA 91325  

Re: P160017  
MiniMed 670G System  
Filed: June 17, 2016  
Procode: OZP

Dear Ms. Jaghasbanian:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the Medtronic MiniMed 670G System. This device is indicated for the following:

**MiniMed 670G System**

The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed 670G System consists of the following devices: MiniMed 670G Pump, the Guardian Link (3) Transmitter, the Guardian Sensor (3), One-Press Serter, and the Contour NEXT Link 2.4 Glucose Meter. The system requires a prescription.

The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Guardian Sensor (3)
The Guardian Sensor (3) is intended for use with the MiniMed 670G system to continuously monitor glucose levels in persons with diabetes. It is intended to be used for detecting trends and tracking patterns in persons aged fourteen years and older, and to be used by the MiniMed 670G system to automatically adjust basal insulin levels. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. The Guardian Sensor (3) is indicated for 7 days of continuous use.

One-press Serter
The serter is used as an aid for inserting the sensor. It is indicated for single-patient use and it is not intended for multiple-patient use.

Guardian Link (3) Transmitter
The Guardian Link (3) Transmitter is intended for use with the MiniMed 670G System. The Guardian Link (3) Transmitter powers the glucose sensor, collects and calculates sensor data, and wirelessly sends the data to the MiniMed 670G insulin pump. The Transmitter is intended for single-patient multi-use.

Contour NEXT Link 2.4 Glucose Meter
The Contour Next Link 2.4 Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single patient use only and should not be shared. The Contour Next Link 2.4 wireless blood glucose monitoring system is indicated for use with fresh capillary whole blood samples drawn from the fingertip and palm only. The Contour NEXT Test Strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL. The Contour Next Link 2.4 wireless blood glucose monitoring system is intended to be used to transmit glucose values to the MiniMed 670G pump and facilitate transfer of information to Medtronic CareLink Software through the use of radio frequency communication. The Contour Next Link 2.4 Wireless Blood Glucose Monitoring System is not intended for the diagnosis of, or screening for, diabetes mellitus. It is not intended for use on neonates.

We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. In addition, the device is restricted under section 515(d)(1)(B)(ii) of the act in that the following statement must appear prominently and conspicuously in all advertising and promotional materials for this device, as well as prominently and conspicuously immediately
following the Indications for Use statement in the Operators Manual that is to be distributed with 
the device:

IMPORTANT: Medtronic performed an evaluation of the 670G closed loop system and 
determined that it may not be safe for use in children under the age of 7 because of the 
way that the system is designed and the daily insulin requirements. Therefore this device 
should not be used in anyone under the age of 7 years old. This device should also not be 
used in patients who require less than a total daily insulin dose of 8 units per day because 
the device requires a minimum of 8 units per day to operate safely.

FDA has determined that these restrictions on sale and distribution are necessary to provide 
reasonable assurance of the safety and effectiveness of the device. Your device is therefore a 
restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to 
the many other FDA requirements governing the manufacture, distribution, and marketing of 
devices.

Expiration dating for the Sensor component of this device has been established and approved at 
12 months at storage conditions between 36°F to 81°F. This is to advise you that the protocol you 
used to establish this expiration dating is considered an approved protocol for the purpose of 
extending the expiration dating as provided by 21 CFR 814.39(a)(7).

Continued approval of this PMA is contingent upon the submission of periodic reports, required 
under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of 
approval of the original PMA. Two copies of this report, identified as "Annual Report" and 
bearing the applicable PMA reference number, should be submitted to the address below. The 
Annual Report should indicate the beginning and ending date of the period covered by the report 
and should include the information required by 21 CFR 814.84. This is a reminder that as of 
September 24, 2014, class III devices are subject to certain provisions of the final UDI rule. 
These provisions include the requirement to provide a UDI on the device label and packages (21 
CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit 
data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). 
Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after September 24, 
2014, to identify each device identifier currently in use for the subject device, and the device 
identifiers for devices that have been discontinued since the previous periodic report. It is not 
necessary to identify any device identifier discontinued prior to December 23, 2013. For more 
information on these requirements, please see the UDI website, http://www.fda.gov/udi.

In addition to the above, and in order to provide continued reasonable assurance of the safety and 
effectiveness of the device, the Annual Report must include, separately for each model number 
(if applicable), the number of devices sold and distributed during the reporting period, including 
those distributed to distributors. The distribution data will serve as a denominator and provide 
necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA 
evaluates the continued safety and effectiveness of the device.
In addition to the Annual Report requirements, you must provide data in post-approval study (PAS) reports. PAS Progress Reports must be submitted for your study every six (6) months during the first two (2) years of the study and annually thereafter, unless otherwise specified by FDA. Two (2) copies of each report, identified as an "OIR Lead PMA Post-Approval Study Report" in accordance with how the study is identified below and bearing the applicable PMA reference number, should be submitted to the address below.

Within 30 days of your receipt of this letter, you must submit a PMA supplement that includes complete protocol of your post-approval study to provide additional confirmatory safety outcomes data collected in a controlled clinical study for a duration of one year. Your PMA supplement should be clearly labeled as “OIR Lead PMA Post-Approval Study Protocol" as noted above and submitted in triplicate to the address below. Please reference the PMA number above to facilitate processing. If there are multiple protocols being finalized after PMA approval, please submit each protocol as a separate PMA supplement.

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA. In addition, the results from any post approval study should typically be included in the labeling as these data become available. Any updated labeling must be submitted to FDA in the form of a PMA Supplement. For more information on post-approval studies, see the FDA guidance document entitled, "Procedures for Handling Post-Approval Studies Imposed by PMA Order" (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070974.htm).

Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:
1. May have caused or contributed to a death or serious injury; or

2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm.

CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all final labeling. Final labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final labeling is identical to the labeling approved in draft form. If the final labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted in 6 copies, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.
If you have any questions concerning this approval order, please contact Andrea Bell-Vlasov, Ph.D., at 240-402-4977 or andrea.bell-vlasov@fda.hhs.gov.

Sincerely yours,

Alberto Gutierrez -S

Alberto Gutierrez, Ph.D.
Director
Office of In Vitro Diagnostics and Radiological Health
Center for Devices and Radiological Health